Nianxiang Zou

Array ( [id] => 19013012 [patent_doc_number] => 11919927 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-05 [patent_title] => Prefusion-stabilized hMPV F proteins [patent_app_type] => utility [patent_app_number] => 18/296771 [patent_app_country] => US [patent_app_date] => 2023-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 15 [patent_no_of_words] => 25400 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 228 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18296771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19541788 [patent_doc_number] => 20240358824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS THROUGH STIMULATED INNATE IMMUNITY IN COMBINATION WITH ANTIVIRAL COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/194864 [patent_app_country] => US [patent_app_date] => 2023-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12229 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18194864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19541788 [patent_doc_number] => 20240358824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS THROUGH STIMULATED INNATE IMMUNITY IN COMBINATION WITH ANTIVIRAL COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/194864 [patent_app_country] => US [patent_app_date] => 2023-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12229 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18194864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19541788 [patent_doc_number] => 20240358824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS THROUGH STIMULATED INNATE IMMUNITY IN COMBINATION WITH ANTIVIRAL COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/194864 [patent_app_country] => US [patent_app_date] => 2023-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12229 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18194864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20115065 [patent_doc_number] => 12364749 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => RSV F protein mutants [patent_app_type] => utility [patent_app_number] => 18/192352 [patent_app_country] => US [patent_app_date] => 2023-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 31401 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18192352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830857 [patent_doc_number] => 20230399382 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => POLYOMAVIRUS NEUTRALIZING ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/186064 [patent_app_country] => US [patent_app_date] => 2023-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33284 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18186064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18583259 [patent_doc_number] => 20230265519 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST [patent_app_type] => utility [patent_app_number] => 18/185153 [patent_app_country] => US [patent_app_date] => 2023-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 118366 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18185153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18986432 [patent_doc_number] => 20240058401 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => CANCER IMMUNOTHERAPY USING VIRUS PARTICLES [patent_app_type] => utility [patent_app_number] => 18/115066 [patent_app_country] => US [patent_app_date] => 2023-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16109 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18115066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786482 [patent_doc_number] => 20230374613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => PRIMER COMPOSITION FOR RECOMBINASE-POLYMERASE AMPLIFICATION REACTION FOR RAPID DIAGNOSIS OF ISRAELI ACUTE BEE PARALYSIS VIRUS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/170064 [patent_app_country] => US [patent_app_date] => 2023-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3932 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18170064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19042336 [patent_doc_number] => 11931409 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-19 [patent_title] => Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids [patent_app_type] => utility [patent_app_number] => 18/108248 [patent_app_country] => US [patent_app_date] => 2023-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 55 [patent_no_of_words] => 35569 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18108248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18922960 [patent_doc_number] => 20240025964 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/100732 [patent_app_country] => US [patent_app_date] => 2023-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47293 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18100732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18523010 [patent_doc_number] => 20230233664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => Compositions and Methods for Promoting Immune Responses to Human Immunodeficiency Virus [patent_app_type] => utility [patent_app_number] => 18/158940 [patent_app_country] => US [patent_app_date] => 2023-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15107 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18158940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18769447 [patent_doc_number] => 20230364211 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => NUCLEOTIDE SEQUENCE EXPRESSING AN EXOSOME-ANCHORING PROTEIN FOR USE AS VACCINE [patent_app_type] => utility [patent_app_number] => 18/157534 [patent_app_country] => US [patent_app_date] => 2023-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13697 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18157534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597693 [patent_doc_number] => 20230272491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => NON-REPLICATIVE TRANSDUCTION PARTICLES WITH ONE OR MORE NON-NATIVE TAIL FIBERS AND TRANSDUCTION PARTICLE-BASED REPORTER SYSTEMS [patent_app_type] => utility [patent_app_number] => 18/152432 [patent_app_country] => US [patent_app_date] => 2023-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14985 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 239 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18152432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19825343 [patent_doc_number] => 12246097 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-11 [patent_title] => Nanoparticle vaccine adjuvant and methods of use thereof [patent_app_type] => utility [patent_app_number] => 18/151182 [patent_app_country] => US [patent_app_date] => 2023-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 45 [patent_no_of_words] => 16814 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18151182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18374269 [patent_doc_number] => 20230149347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => CXCR4/CXCR7 Blockade and Treatment of Human Papilloma Virus-Associated Disease [patent_app_type] => utility [patent_app_number] => 18/149922 [patent_app_country] => US [patent_app_date] => 2023-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11353 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18149922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18629539 [patent_doc_number] => 20230288421 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => SARS-COV-2 SERUM ANTIBODY PROFILING [patent_app_type] => utility [patent_app_number] => 18/145772 [patent_app_country] => US [patent_app_date] => 2022-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18145772 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18647885 [patent_doc_number] => 20230293662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE HUMAN PAPILLOMAVIRUS FORMULATIONS [patent_app_type] => utility [patent_app_number] => 18/069058 [patent_app_country] => US [patent_app_date] => 2022-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11270 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18069058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483669 [patent_doc_number] => 20230210970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => HETEROLOGOUS COMBINATION PRIME:BOOST THERAPY AND METHODS OF TREATMENT [patent_app_type] => utility [patent_app_number] => 18/069159 [patent_app_country] => US [patent_app_date] => 2022-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18006 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18069159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19519864 [patent_doc_number] => 12121562 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => Antigenic Epstein Barr virus polypeptides [patent_app_type] => utility [patent_app_number] => 18/067940 [patent_app_country] => US [patent_app_date] => 2022-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 90 [patent_no_of_words] => 23659 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18067940 [rel_patent_id] =>[rel_patent_doc_number] =>)